Upstream Bio, Stock Beneish M Score

UPB Stock   17.12  2.07  10.79%   
This module uses fundamental data of Upstream Bio, to approximate the value of its Beneish M Score. Upstream Bio, M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Upstream Bio, Piotroski F Score and Upstream Bio, Altman Z Score analysis.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.
  
At this time, Upstream Bio,'s M Score is unavailable. The earnings manipulation may begin if Upstream Bio,'s top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Upstream Bio, executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Upstream Bio,'s earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.38
Beneish M Score - Unavailable
Elasticity of Receivables

1.14

Focus
Asset Quality

N/A

Focus
Expense Coverage

1.06

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

1.06

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

0.83

Focus
Financial Leverage Condition

N/A

Focus

Upstream Bio, Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Upstream Bio,'s auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables93.1 K98 K
Notably Down
Slightly volatile
Total RevenueM2.4 M
Significantly Down
Slightly volatile
Total Assets74.6 M117.2 M
Way Down
Slightly volatile
Total Current Assets74.4 M117 M
Way Down
Slightly volatile
Non Current Assets Total205.2 K202 K
Fairly Up
Slightly volatile
Selling General Administrative9.4 M10.7 M
Fairly Down
Slightly volatile
Total Current Liabilities6.3 M6.5 M
Sufficiently Down
Slightly volatile
Non Current Liabilities Total194.5 M233.8 M
Significantly Down
Slightly volatile

Upstream Bio, Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Upstream Bio,'s different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Upstream Bio, in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Upstream Bio,'s degree of accounting gimmicks and manipulations.

Did you try this?

Run Commodity Directory Now

   

Commodity Directory

Find actively traded commodities issued by global exchanges
All  Next Launch Module

About Upstream Bio, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Upstream Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Upstream Bio, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio, Stock:
Check out Upstream Bio, Piotroski F Score and Upstream Bio, Altman Z Score analysis.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio,. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Upstream Bio, is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio,'s market value can be influenced by many factors that don't directly affect Upstream Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.